2014 journal article

Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure


MeSH headings : Animals; Cardiomyopathy, Hypertrophic / drug therapy; Cardiomyopathy, Hypertrophic / mortality; Cardiomyopathy, Hypertrophic / veterinary; Cardiotonic Agents / therapeutic use; Case-Control Studies; Cat Diseases / drug therapy; Cat Diseases / mortality; Cats; Female; Heart Failure / drug therapy; Heart Failure / mortality; Heart Failure / veterinary; Male; Pyridazines / therapeutic use; Retrospective Studies
TL;DR: The addition of pimobendan to traditional treatment for CHF may provide a substantial clinical benefit in survival time for HCM-affected cats with CHF and possibly HOCM- affected cats withCHF. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (Web of Science; OpenAlex)
Sources: Web Of Science, ORCID
Added: August 6, 2018

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.